Plain-English translation of NCT05646394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is collecting information from people with antiphospholipid syndrome — a rare immune disorder that makes blood clots more likely — who have experienced arterial blood clots (clots in arteries). Researchers want to compare three main approaches to preventing future clots: warfarin (a blood thinner) plus low-dose aspirin, warfarin alone at different strengths, or (two antiplatelet medications together). By gathering real-world data from patients receiving these different treatments, the study aims to figure out which approach is most effective and safest.
Right now, doctors don't have clear evidence about which blood-thinning strategy works best for people with antiphospholipid syndrome who have had arterial clots. This registry will help answer that question by collecting information from many patients to see which treatment approach leads to fewer repeat clots and fewer serious bleeding complications.
You likely qualify if…
You likely don't qualify if…
As a participant, you would not need to start any new medication — this is a registry study that collects information from patients already receiving one of these standard treatment approaches. You would share your medical records and health information with the research team, and likely have periodic check-ins (either in person or by phone/mail) to report how you are doing, any side effects, and whether you have had any new blood clots or bleeding problems. The study will track your health over time to compare which treatment approach works best for people like you.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Argentina
Canada